Modular DHA Synthase Enzyme for Polyunsaturated Fatty Acid Production

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for producing polyunsaturated fatty acids (PUFAs), particularly docosahexaenoic acid (DHA), from natural sources and chemical synthesis are insufficient for long-term commercial needs, and the biochemical basis of DHA synthesis in Crypthecodinium cohnii has not been well understood, lacking identified genes or proteins associated with DHA synthesis.

Innovation Solution

Identification of a modular Type I polyketide synthase (PKS) enzyme, specifically a docosahexaenoic acid synthase, in Crypthecodinium cohnii, which catalyzes de novo production of DHA using malonyl-CoA as a substrate without requiring molecular oxygen, and its expression in host organisms to enhance DHA production.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If conventional elongation and desaturation pathways are used for PUFA production, then existing enzymatic pathways can be utilized, but the production capacity is insufficient for long-term commercial needs

Engineering Contradiction:
ImprovePUFA production capacityVSAvoidsupply of PUFAs
Core Design Contradiction:
ProductivityVSQuantity of substance

Solution Approach 1:

The patent divides the PUFA synthesis pathway into modular domains within a Type I polyketide synthase system. Each module contains specific enzymatic activities (ketosynthase, acyltransferase, dehydratase, enoylreductase, beta-keto reductase) that can be independently optimized and assembled. This modular architecture enables enhanced productivity by allowing systematic optimization of individual modules while maintaining overall pathway functionality, directly addressing the insufficient production capacity of conventional pathways.

Inventive Principle:
Principle #1Segmentation

2Productivity

If Type I polyketide synthase system is used for de novo PUFA synthesis, then production capacity is enhanced, but the system complexity increases compared to conventional pathways

Engineering Contradiction:
ImproveDHA production efficiencyVSAvoidenzymatic pathway complexity
Core Design Contradiction:
ProductivityVSDevice complexity

Solution Approach 1:

The patent merges multiple enzymatic activities (ketosynthase, acyltransferase, dehydratase, enoylreductase, beta-keto reductase) into a single integrated Type I polyketide synthase complex. This consolidation reduces the number of separate enzymes and regulatory elements needed, simplifying the overall system architecture while maintaining enhanced productivity. The merged system operates as a coordinated unit, reducing complexity compared to having separate enzymes for each reaction step.

Inventive Principle:
Principle #5Merging (Combining)

3Adaptability or versatility

If conventional desaturases are used for double bond formation, then oxygen-dependent reactions occur, but this limits the synthesis pathway flexibility and efficiency

Engineering Contradiction:
Improvesynthesis pathway flexibilityVSAvoidenergy consumption of synthesis pathway
Core Design Contradiction:
Adaptability or versatilityVSUse of energy by moving object

Solution Approach 1:

The patent fundamentally changes the reaction parameters by replacing oxygen-dependent desaturase reactions with oxygen-independent Type I PKS-mediated dehydratase and enoylreductase reactions. This parameter change eliminates the requirement for molecular oxygen, allowing the pathway to operate under anaerobic conditions and reducing oxidative stress. The energy parameters are also optimized through the coordinated action of coupled reductase reactions that use NADPH efficiently, enhancing pathway versatility and reducing energy consumption.

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The modular DHA synthase enables efficient production of DHA in genetically modified organisms, overcoming the limitations of existing methods and providing a novel pathway for DHA synthesis, potentially increasing DHA accumulation in hosts.

Implementation Method 1

Identification of a modular Type I polyketide synthase (PKS) enzyme, specifically a docosahexaenoic acid synthase, in Crypthecodinium cohnii, which catalyzes de novo production of DHA using malonyl-CoA as a substrate without requiring molecular oxygen

Methodology Applied
Scientific EffectEnzyme catalysis: Enzyme

Data Source

PatentEP3302032B1Production of polyunsaturated fatty acids (PUFAS) using a novel modular docosahexaenoic acid (DHA) synthase
Publication Date: 2021.12.15 DSM IP ASSETS BV
  • EP3302032B1 patent drawingFigure 1A~1B
  • EP3302032B1 patent drawingFigure 1C~2
  • EP3302032B1 patent drawingFigure 3

AI summary

This disclosure concerns a novel modular docosahexaenoic acid (DHA) synthase and recombinant host organisms genetically modified with such synthase and one or more accessory proteins that allow for and/or improve the production of PUFAs in the host organism. The disclosure also concerns methods of making and using such organisms as well as products obtained from such organisms.